These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 29554495)

  • 1. Cancer vaccines: translation from mice to human clinical trials.
    Maeng H; Terabe M; Berzofsky JA
    Curr Opin Immunol; 2018 Apr; 51():111-122. PubMed ID: 29554495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer vaccine strategies: translation from mice to human clinical trials.
    Berzofsky JA; Terabe M; Trepel JB; Pastan I; Stroncek DF; Morris JC; Wood LV
    Cancer Immunol Immunother; 2018 Dec; 67(12):1863-1869. PubMed ID: 29143114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic cancer vaccines: From initial findings to prospects.
    Song Q; Zhang CD; Wu XH
    Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune based therapies in cancer.
    Krüger C; Greten TF; Korangy F
    Histol Histopathol; 2007 Jun; 22(6):687-96. PubMed ID: 17357098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent developments in therapeutic cancer vaccines.
    Morse MA; Chui S; Hobeika A; Lyerly HK; Clay T
    Nat Clin Pract Oncol; 2005 Feb; 2(2):108-13. PubMed ID: 16264883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promises and limitations of murine models in the development of anticancer T-cell vaccines.
    Lévy F; Colombetti S
    Int Rev Immunol; 2006; 25(5-6):269-95. PubMed ID: 17169777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immunotherapy.
    Bender E
    Nature; 2017 Dec; 552(7685):S61. PubMed ID: 29293244
    [No Abstract]   [Full Text] [Related]  

  • 9. Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.
    Gatti-Mays ME; Redman JM; Collins JM; Bilusic M
    Hum Vaccin Immunother; 2017 Nov; 13(11):2561-2574. PubMed ID: 28857666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer vaccines. Any future?
    Myc LA; Gamian A; Myc A
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunotherapy: new insights].
    Geissler M; Weth R
    Praxis (Bern 1994); 2002 Dec; 91(51-52):2236-46. PubMed ID: 12564040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New frontiers in cell-based immunotherapy of cancer.
    D'Elios MM; Del Prete G; Amedei A
    Expert Opin Ther Pat; 2009 May; 19(5):623-41. PubMed ID: 19441938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
    Speiser DE; Romero P
    Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer vaccines: what do we need to measure in clinical trials?
    Kudrin A
    Hum Vaccin Immunother; 2014; 10(11):3236-40. PubMed ID: 25483508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of cancer by active vaccination: does allogeneic bone marrow transplantation after non-myeloablative conditioning provide a new option?
    Zöller M
    Technol Cancer Res Treat; 2003 Jun; 2(3):237-60. PubMed ID: 12779354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A power surge for cancer immunotherapy: antibodies, vaccines, and engineered T cells fuel new optimism.
    Nelson B
    Cancer Cytopathol; 2014 Jan; 122(1):1-2. PubMed ID: 24424750
    [No Abstract]   [Full Text] [Related]  

  • 18. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
    Seremet T; Brasseur F; Coulie PG
    Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer vaccines: preclinical studies and novel strategies.
    Palena C; Abrams SI; Schlom J; Hodge JW
    Adv Cancer Res; 2006; 95():115-45. PubMed ID: 16860657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer.
    Kerr MD; McBride DA; Chumber AK; Shah NJ
    Expert Opin Drug Discov; 2021 Jan; 16(1):89-99. PubMed ID: 32867561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.